8-K: Outlook Therapeutics Secures $33.1 Million Financing to Repay Debt and Advance ONS-5010 Program

Outlook Therapeutics enters into a securities purchase agreement for $33.1 million to refinance existing debt and support its ONS-5010 development program.

Summary

• Outlook Therapeutics has entered into a Securities Purchase Agreement (SPA) with Avondale Capital, LLC to issue an unsecured convertible promissory note with a face amount of $33.1 million.
• The company intends to use the proceeds to repay its existing debt of approximately $32.37 million with Streeterville Capital, LLC.
• The remaining funds will support the ONS-5010 development program, working capital, and other general corporate purposes.
• The closing of the transaction is subject to stockholder approval for the issuance of shares exceeding 19.99% of the outstanding common stock upon conversion of the note.
• The note will bear interest at the prime rate plus 3% (with a floor of 9.5%) and matures on July 1, 2026.
• Outlook Therapeutics is obligated to repay at least $3 million of the outstanding balance each calendar quarter, starting in the second quarter of 2025.
• Avondale Capital, LLC has the right to convert all or any portion of the outstanding balance under the Note into a number of shares of Common Stock obtained by dividing the amount of the Note being converted by the Conversion Price beginning six months following the issuance of the Note or the date on which the Registration Statement is declared effective.
• The conversion price is initially set at $2.26 per share, subject to adjustments.
• The lender's ownership is capped at 4.99% of the outstanding common stock, which can be increased to 9.99% if the market capitalization is less than $25 million.
• The company has agreed to file a registration statement for the resale of shares issued upon conversion of the note within seven days of closing and to use commercially reasonable efforts to have it declared effective within 45 days.
• Failure to meet the effectiveness deadline will result in an automatic increase of 0.5% to the outstanding balance every 30 days until effectiveness.
• The lender has a participation right to acquire up to 10% of certain debt obligations or convertible securities issued by the company during the term of the note.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The financing provides needed capital, but also introduces potential dilution and restrictive covenants.

Positives

• The financing allows Outlook Therapeutics to refinance existing debt, reducing financial obligations to Streeterville Capital, LLC.
• The remaining proceeds will support the development of ONS-5010, a key program for the company.
• The agreement includes a participation right for the lender, potentially attracting further investment in the future.
• The company has the right to convert all or any portion of the outstanding balance under the Note into shares of Common Stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the Conversion Commencement Date, the daily volume-weighted average price of our common stock on Nasdaq equals or exceeds $3.00 per share (subject to adjustments for stock splits and stock combinations) for a period of 30 consecutive trading days and the median daily dollar trading volume during the preceding 30 trading day period is greater than or equal to $1,000,000.

Negatives

• The company needs to obtain stockholder approval for the issuance of shares exceeding 19.99% of the outstanding common stock.
• The agreement contains restrictive covenants that limit the company's ability to issue certain debt or equity securities without the lender's consent.
• The lender has the right to increase the balance of the note by 10% for a Major Trigger Event and 5% for a Minor Trigger Event.
• Following an Event of Default, the Lender may accelerate the Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid.

Risks

• Failure to obtain stockholder approval could jeopardize the closing of the transaction.
• Inability to meet the registration statement effectiveness deadline will increase the outstanding balance of the note.
• The company's operations are subject to Trigger Events and Events of Default, which could lead to increased debt or acceleration of the note.
• The company's ability to raise capital in the future is restricted by the lender's participation right and consent requirements.
• The conversion price may decrease following a Major Trigger Event, potentially leading to greater dilution for existing shareholders.

Future Outlook

The company expects to close the transaction shortly after its 2025 annual meeting of stockholders, subject to customary closing conditions and stockholder approval. The company plans to file a resale registration statement to register the resale of the shares of common stock underlying the Note.

Industry Context

This financing is typical for small biotech companies seeking to fund drug development programs. Convertible notes are a common instrument, allowing companies to access capital while deferring equity dilution.

Comparison to Industry Standards

• Comparable companies in the biotech sector often utilize convertible notes to fund clinical trials and operations.
• The interest rate and conversion terms are within the typical range for such financings, but the specific terms depend on the company's risk profile and market conditions.
• The lender's participation right is a common feature, providing them with the opportunity to maintain their investment level in future financings.
• A comparable company is Aerie Pharmaceuticals who also used convertible notes to fund their glaucoma drug development.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the note.
• Employees will benefit from the continued funding of the ONS-5010 development program.
• Creditors will be impacted by the repayment of existing debt.
• The company's suppliers and customers may see continued operations due to the financing.

Next Steps

• Obtain stockholder approval for the issuance of shares upon conversion of the note.
• Close the transaction with Avondale Capital, LLC.
• File a registration statement for the resale of shares issued upon conversion.
• Utilize the proceeds to repay existing debt and support the ONS-5010 development program.

Key Dates